Upfront Chemohormonal Therapy for Prostate Cancer: Neutropenia and G-CSF Use.

Upfront Chemohormonal Therapy for Prostate Cancer: Neutropenia and G-CSF Use.

Authors

  • Sebastiano Buti Oncology Unit, University Hospital of Parma
  • Melissa Bersanelli Oncology Unit, University Hospital of Parma

Keywords:

neutropenia, GCS-F, chemohormonal therapy, docetaxel, prostate cancer, CHAARTED

Abstract

After the publication of the results of CHAARTED trial, we discuss an issue of clinical interest about toxicity of this treatment and its prophylactic management. The low rates of neutropenia reported in CHAARTED trial population, compared to those of similar previous studies, need further clarifications about the use of G-CSF, not described by the authors, in order to reproduce this hematological tolerability also in everyday clinical practice. We highlighted the importance of toxicity management and prevention in order to better apply the results of this promising trial in real life patient care.

Author Biographies

Sebastiano Buti, Oncology Unit, University Hospital of Parma

None to declare

Melissa Bersanelli, Oncology Unit, University Hospital of Parma

None to declare

Downloads

Published

06-05-2016

Issue

Section

LETTERS TO EDITOR

How to Cite

1.
Buti S, Bersanelli M. Upfront Chemohormonal Therapy for Prostate Cancer: Neutropenia and G-CSF Use. Acta Biomed [Internet]. 2016 May 6 [cited 2024 Jul. 15];87(1):108-9. Available from: https://mattioli1885journals.com/index.php/actabiomedica/article/view/4906